Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression?

Area of Science:

• Cardiovascular Medicine
• Medical Imaging Technology

Background:

• Coronary artery disease (CAD) clinical trials often rely on clinical events as primary endpoints.
• Intravascular ultrasound (IVUS) provides detailed imaging of coronary plaque.
• The utility of IVUS-derived plaque progression as a surrogate for clinical events is under investigation.

Purpose of the Study:

• To evaluate whether progressive changes in IVUS-derived plaque size can reliably predict cardiovascular event risk in coronary disease trials.
• To determine if IVUS can serve as an efficient surrogate endpoint for clinical events in these trials.

Main Methods:

• Review of existing clinical trial data utilizing IVUS.
• Analysis of IVUS-derived plaque size indexes and their correlation with clinical outcomes.
• Comparison of IVUS findings with quantitative arteriography results.
• Discussion of the limitations and assumptions inherent in IVUS measurements.

Main Results:

• The question of whether IVUS-derived plaque changes are sufficiently predictive of cardiovascular events remains unanswered by current trial data.
• Evidence suggests IVUS *may* be a viable surrogate, but significant concerns persist.
• Concerns include physical limitations, fundamental assumptions, and interpretation challenges of IVUS measurements.

Conclusions:

• IVUS is a powerful tool for visualizing coronary plaque, but its role as a surrogate for clinical events in trials requires further validation.
• Despite potential, the reliability of IVUS for predicting cardiovascular risk cannot be assumed due to existing limitations.
• Further research and standardization are needed to establish IVUS as a definitive surrogate endpoint in coronary disease trials.